米吉珠单抗对克罗恩病组织学缓解的随机对照2期试验效果
基于SERENITY试验170例克罗恩病患者的活检标本,评估米吉珠单抗的组织学疗效及其与内镜和1年结局的关联。第12周米吉珠单抗1000 mg的组织学应答率(66% vs 27%,P<.001)和缓解率(26% vs 6%,P<.01)均高于安慰剂;早期组织学-内镜联合应答与治疗1年后内镜缓解相关(P=.003)。
要点
- 第12周米吉珠单抗1000 mg组织学应答66% vs 安慰剂27%(P<.001),缓解26% vs 6%(P<.01)。
- 第12周组织学与内镜应答一致率69%(κ=0.40),缓解一致率83%(κ=0.38)。
- 治疗1年时,第12周组织学-内镜联合应答者内镜缓解率45%,均无应答者4%(P=.003)。
核心结论
- 在一项2期数据的事后分析中,米吉珠单抗在52周内诱导并维持了克罗恩病的组织学应答和缓解。
- 早期组织学-内镜联合应答与米吉珠单抗治疗1年后的内镜缓解相关。
研究设计与样本
- SERENITY试验的随机对照2期研究事后分析,共纳入170例参与者。
- 于第0、12、52周对每例参与者的1个回肠和4个结肠节段活检标本进行评估。
主要发现
- 第12周,米吉珠单抗1000 mg的组织学应答率高于安慰剂(66% vs 27%;P<.001),组织学缓解率亦高于安慰剂(26% vs 6%;P<.01)。
- 1年时各率数值上相似:米吉珠单抗汇总应答率46%-69%,缓解率13%-31%。
- 第12周组织学与内镜应答一致率为69%(Cohen κ=0.40),缓解一致率为83%(κ=0.38),分析涵盖包括安慰剂在内的所有汇总组。
- 1年时,接受任何剂量米吉珠单抗且达到内镜缓解的参与者百分比因第12周应答而异:组织学应答20%、内镜应答25%、组织学-内镜联合应答45%、均无应答4%(P=.003)。
关键数值与推荐
- 第12周和第52周组织学应答标准:无上皮中性粒细胞或上皮损伤,或Robarts组织病理学指数或活动性全球组织学疾病活动评分下降>50%。
- 组织学缓解标准:所有活检标本均须满足无黏膜中性粒细胞且无上皮损伤。
局限性
- 原文为2期数据的事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Histologic evaluation of mucosal healing in Crohn's disease is an evolving treatment target. We evaluated histologic outcomes for mirikizumab efficacy and associations with endoscopic and 1-year outcomes. METHODS: Biopsy specimens from 1 ileal and 4 colonic segments were evaluated at weeks 0, 12, and 52 from each of the 170 SERENITY participants. Criteria for the weeks 12 and 52 histologic response were no epithelial neutrophils or epithelial damage, or >50% decrease in either the Robarts Histopathology Index or the active Global Histologic Disease Activity Score, and remission (no mucosal neutrophils and no epithelial damage) had to be met in all biopsy specimens. Agreement was evaluated between histologic and endoscopic end points. Associations between 1-year outcomes and week 12 histologic and endoscopic response were evaluated. RESULTS: At week 12, 1000 mg mirikizumab resulted in greater rates of histologic response (66% vs 27%; P < .001) and remission (26% vs 6%; P < .01) than placebo. Rates were numerically similar at 1 year (mirikizumab pooled response, 46%-69%; remission, 13%-31%). Agreement between week 12 histologic and endoscopic response was 69% (Cohen's kappa coefficient [κ] = 0.40) and remission was 83% (κ = 0.38) in all pooled arms, including placebo. At 1 year, the percentage of participants who received any dose of mirikizumab and achieved endoscopic remission differed by their week 12 response: histologic (20%), endoscopic (25%), combined histology-endoscopy (45%), or neither (4%) (P = .003). CONCLUSIONS: In a post hoc analysis of phase 2 data, mirikizumab induced and sustained histologic response and remission in Crohn's disease over 52 weeks. Early combined histologic-endoscopic response was associated with endoscopic remission after 1 year of treatment with mirikizumab (ClinicalTrials.gov NCT02891226).
引用
- Magro F, Protic M, De Hertogh G, et al. Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial. Clin Gastroenterol Hepatol. 2023. PMID: 37993033. doi:10.1016/j.cgh.2023.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。